Tech Center 1600 • Art Units: 1623 1691 1693
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18192291 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | Non-Final OA | Illumina, Inc. |
| 17965573 | GLYCOLIPID COMPOSITIONS AND METHODS OF USE | Final Rejection | President and Fellows of Harvard College |
| 18256401 | REDUCTION OF RANCIDITY OF VEGETABLE OILS | Final Rejection | DSM IP Assets B.V. |
| 17425469 | CANCER VACCINE FORMULATION | Non-Final OA | ASAHI KASEI KABUSHIKI KAISHA |
| 18032149 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Final Rejection | North Carolina State University |
| 18226071 | Methods and Compositions for Treating Leucine Rich Repeat Kinase 2 (LRRK2)-Associated Disorder or Condition | Non-Final OA | University of Connecticut |
| 17594415 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | Non-Final OA | 3M INNOVATIVE PROPERTIES COMPANY |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | Non-Final OA | Children's Medical Center Corporation |
| 18561470 | PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID COMPLEX FOR PREVENTION OR TREATMENT OF SKIN DISEASE | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17759597 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17597878 | ANTICANCER AGENTS | Final Rejection | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 18109021 | CORONAVIRUS TREATMENT COMPOSITION AND METHOD | Non-Final OA | University of Tennessee Research Foundation |
| 17431462 | Methods for purifying bacterial polysaccharides | Non-Final OA | Pfizer Inc. |
| 17629654 | INHIBITORS OF ANTIBIOTIC RESISTANCE MEDIATED BY ARNT | Final Rejection | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18288397 | MALTOSIDE-, LACTOBIONAMIDE-, MONOGLUCOSIDE-, BRANCHED DIGLUCOSIDE-, SULFOBETAINE-, SULFATE- OR AMINOOXIDE-BASED PERFLUORINATED DETERGENTS AND THEIR USE IN MEMBRANE-PROTEINS APPLICATIONS | Non-Final OA | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER |
| 18256057 | FIBRE MIXTURE FOR YOUNG CHILDREN | Final Rejection | N.V. Nutricia |
| 18329381 | 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE DEPENDENT TELOMERE DYSFUNCTION AND CELL DEATH IN VARIOUS MODELS OF THERAPY-RESISTANT CANCER CELLS | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18284177 | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS | Non-Final OA | ModernaTX, Inc. |
| 18565881 | STERILIZED MULTICOMPONENT COMPOSITION FOR REMOVAL OF PARTICLES | Non-Final OA | PURENUM GMBH |
| 18556489 | NOVEL SPINOSYN PRODRUGS | Non-Final OA | Acies Bio d.o.o. |
| 18553868 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | Non-Final OA | BACHEM HOLDING AG |
| 17761376 | Antibiotic Compounds | Non-Final OA | UNIVERSITEIT LEIDEN |
| 17911712 | Compounds Useful in HIV Therapy | Final Rejection | VIIV HEALTHCARE COMPANY |
| 18259146 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Non-Final OA | GALECTO BIOTECH AB |
| 18039107 | IMMUNOTHERAPY FOR CANCER | Non-Final OA | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOL |
| 18142198 | COMPOSITION AND METHODS FOR GENERATING A DERMAL FILLER | Final Rejection | Allure Medical Spa PLLC |
| 18135229 | Method and compounds for inhibiting the MCM complex and their application in cancer treatment | Non-Final OA | Macau University Of Science And Technology |
| 18295247 | METHYLCOBALAMIN OPHTHALMIC PREPARATION AND USE THEREOF | Non-Final OA | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY |
| 18029189 | ANTI-INFECTIVE DOSAGE FORMS FOR PRODUCING A NASAL RINSE | Non-Final OA | SIDROGA GESELLSCHAFT FÜR GESUNDHEITSPRODUKTE MBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy